Ankrin Therapeutics ApS - CVR: 39788705

2023, DKK

10.07.2024

Bruttoresultat

-498'

Primær drift

-2.092'

Årets resultat

-2.334'

Aktiver

1.614'

Kortfristede aktiver

1.614'

Egenkapital

-6.779'

Afkastningsgrad

-130 %

Soliditetsgrad

-420 %

Likviditetsgrad

+500%

Resultat

10.07.2024

Årsrapport	2023 10.07.2024	2022 30.06.2023	2021 01.07.2022	2020 05.07.2021	2018 18.05.2020
Nettoomsætning
Bruttoresultat	-497.960	-1.024.945	-2.427.405	-2.066.728	-3.755.400
Resultat af primær drift	-2.092.152	-3.209.199	-5.152.880	-3.894.011	-5.001.750
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0
Finansielle indtægter	5	0	0	20	0
Finansieringsomkostninger	-593.617	-294.083	-389.767	-448.503	-357.334
Andre finansielle omkostninger	0	0	0	0	0
Resultat før skat	-2.685.764	-3.503.282	-5.542.647	-4.342.494	-5.359.084
Resultat	-2.334.458	-2.732.702	-4.493.439	-3.485.420	-4.392.910
Forslag til udbytte	0	0	0	0	0

Aktiver

10.07.2024

Årsrapport	2023 10.07.2024	2022 30.06.2023	2021 01.07.2022	2020 05.07.2021	2018 18.05.2020
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	394.228	1.460.701	1.220.766	1.273.850	1.101.295
Likvider	1.220.229	2.195.534	5.358.029	9.440.298	3.323.321
Kortfristede aktiver	1.614.457	3.656.235	6.578.795	10.714.148	4.424.616
Immaterielle aktiver og goodwill	0	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0	0
Materielle aktiver	0	0	0	0	0
Langfristede aktiver	0	0	0	0	0
Aktiver	1.614.457	3.656.235	6.578.795	10.714.148	4.424.616

Aktiver

10.07.2024

Passiver

10.07.2024

Årsrapport	2023 10.07.2024	2022 30.06.2023	2021 01.07.2022	2020 05.07.2021	2018 18.05.2020
Forslag til udbytte	0	0	0	0	0
Egenkapital	-6.779.478	-4.445.020	-1.712.318	2.781.121	-4.377.910
Hensatte forpligtelser	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0
Anden langfristet gæld		7.562.947	74.627	74.627	47.800
Leverandører af varer og tjenesteydelser	95.639	341.456	521.077	458.779	683.315
Kortfristede forpligtelser	285.957	538.308	990.667	968.193	925.959
Gældsforpligtelser	8.393.935	8.101.255	8.291.113	7.933.027	8.802.526
Forpligtelser	8.393.935	8.101.255	8.291.113	7.933.027	8.802.526
Passiver	1.614.457	3.656.235	6.578.795	10.714.148	4.424.616

Passiver

10.07.2024

Nøgletal

10.07.2024

Årsrapport	2023 10.07.2024	2022 30.06.2023	2021 01.07.2022	2020 05.07.2021	2018 18.05.2020
Afkastningsgrad	-129,6 %	-87,8 %	-78,3 %	-36,3 %	-113,0 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	34,4 %	61,5 %	262,4 %	-125,3 %	100,3 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-352,4 %	-1.091,3 %	-1.322,0 %	-868,2 %	-1.399,7 %
Soliditestgrad	-419,9 %	-121,6 %	-26,0 %	26,0 %	-98,9 %
Likviditetsgrad	564,6 %	679,2 %	664,1 %	1.106,6 %	477,8 %

Resultat

10.07.2024

Gæld

10.07.2024

Årsrapport

10.07.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 10.07.2024)

Information om virksomhedens regnskabsklasse:The annual report for Ankrin Therapeutics ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises. The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Beretning

10.07.2024

Dato for ledelsens godkendelse af årsrapporten:2024-07-08

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties as to going concern. The preparation of the financial statements reguires an assessment in the validity of the going concern assumption. The management has reviewed projections for a period of 12 months from the date of approval of the financial statements as well as potential opportunities. Any potential short falls in funding have been identified and the steps to which the management is able to mitigate such scenarios and/or defer or curtail discretionary expenditures have been taken. The management recognises that there is a level of uncertainty as to going concern. However, the management has a reasonable expectation that the company has sufficient resources to continue operations and existence for the foreseeable future. Accordingly, the management believes it is appropriate to adopt the going concern basis in the preparation of the financial statements.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have approved the annual report of Ankrin Therapeutics ApS for the financial year 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Description of key activities of the company Like previous years, the activities are to carry out research and development enabling later manufacturing and commercialization of medicinal products for the treat of cancer.